Physician profile
William Chung
NPI 1043809031
$6,985.31
in general payments reported to CMS, 2019-2025
22 companies · $2,914 in 2025
The $2,914 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.07 · 2022: $197 · 2023: $1,423 · 2024: $2,414 · 2025: $2,914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,750.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,719.84 | 2023-2025 | Vemlidy, Livdelzi |
| Amgen INC. | $867.24 | 2022-2025 | Evenity, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $601.23 | 2023-2025 | Xifaxan, Trulance |
| Esperion Therapeutics, INC. | $513.96 | 2023-2025 | Nexletol |
| Ibsa Pharma INC. | $476.44 | 2022-2024 | Tirosint, Licart, Licart |
| Phathom Pharmaceuticals, INC. | $345.11 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $343.74 | 2024-2025 | Ibsrela |
| Exact Sciences Corporation | $334.48 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $281.42 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $279.24 | 2023-2025 | Jardiance |
| Lilly USA, LLC | $226.07 | 2023-2025 | Jardiance, Emgality |
| Merck Sharp & Dohme LLC | $181.40 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
| Novo Nordisk INC | $151.60 | 2022-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $150.18 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $132.75 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $116.23 | 2024-2025 | Trelegy Ellipta |
| Amarin Pharma, INC. | $99.16 | 2021-2023 | |
| Kestra Medical Technology Services, INC. | $49.74 | 2024 | Assure Wcd |
| Shield Therapeutics INC | $48.37 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $36.33 | 2024 | Airsupra, Farxiga |
| Sumitomo Pharma America, INC. | $16.71 | 2025 | Gemtesa |
| Ironwood Pharmaceuticals, INC | $14.07 | 2023 | Linzess |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.